Last Updated : April 29, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort descending |
---|---|---|---|---|---|---|
Opdivo | Nivolumab | Melanoma Adjuvant Therapy | Reimburse with clinical criteria and/or conditions | Complete | ||
Adcetris (Resubmission) | Brentuximab Vedotin | Hodgkin lymphoma (HL) | Do not reimburse | Complete | ||
Xtandi | Enzalutamide | Non-metastatic castration-resistant prostate cancer (nm-CRPC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Unituxin | Dinutuximab | Neuroblastoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Radicava | edaravone | amyotrophic lateral sclerosis | Reimburse with clinical criteria and/or conditions | Complete | ||
Eucrisa | crisaborole | atopic dermatitis | Do not reimburse | Complete | ||
Cinqair | reslizumab | Asthma, eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | ||
Fasenra | benralizumab | Asthma, severe eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | ||
Nucala | mepolizumab | Asthma, severe eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | ||
Folotyn | Pralatrexate | Peripheral T-Cell Lymphoma (PTCL) | Reimburse with clinical criteria and/or conditions | Complete |